EMSY: A Potential Drug Target for Breast Cancer (G56946)

Target Name: EMSY

NCBI ID: G56946

EMSY

EMSY: A Potential Drug Target for Breast Cancer

BRCA2 is a tumor suppressor gene that plays a crucial role in the development and progression of breast cancer. Mutations in the BRCA2 gene have been identified as a risk factor for breast cancer and other types of cancer. One of the known mutations is the interstitial trastuzumous retinoblastoma (ITR), which is a type of breast cancer that develops in the interstitium, a tissue that is not normally affected by breast cancer.

EMSY is a transcriptional repressor that interacts with BRCA2 and has been identified as a potential drug target for breast cancer. In this article, we will discuss the structure and function of EMSY, its potential as a drug target, and the research that has been done to investigate its potential as a treatment for breast cancer.

Structure and Function

EMSY is a non-coding RNA molecule that was identified as a potential drug target for breast cancer. It is composed of 198 amino acid residues and has a calculated molecular weight of 21.1 kDa. EMSY is expressed in most tissues and is primarily localized to the cytoplasm.

EMSY has been shown to interact with BRCA2, a tumor suppressor gene that plays a crucial role in the development and progression of breast cancer.BRCA2 is a double-stranded DNA gene that has four known splice variants: BRCA2-1, BRCA2-2, BRCA2-3, and BRCA2-4. All of these splice variants are expressed in most tissues and have been shown to play a role in the development and progression of breast cancer.

EMSY has been shown to physically interact with BRCA2 by using a unique conformational change that allows it to bind to the BRCA2 protein. This interaction between EMSY and BRCA2 has been shown to enhance the repressive effects of BRCA2 and increase the likelihood of gene expression.

EMSY has also been shown to play a role in the regulation of cellular processes that are important for cancer development. For example, EMSY has been shown to be involved in the regulation of cell cycle progression, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

Potential as a Drug Target

EMSY has been identified as a potential drug target for breast cancer due to its ability to interact with BRCA2 and its role in the regulation of cellular processes that are important for cancer development. Studies have shown that inhibiting EMSY activity can lead to a reduction in the growth and survival of breast cancer cells.

One of the known drug targets for breast cancer is the inhibition of the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and has been shown to be involved in the development and progression of breast cancer.

EMSY has been shown to interact with the PI3K/Akt signaling pathway, and inhibition of its activity has been shown to reduce the growth and survival of breast cancer cells. This suggests that EMSY may be an effective drug target for breast cancer.

Another potential drug target for breast cancer is the inhibition of the ERK1/2 signaling pathway. This pathway is involved in the regulation of cell growth, survival, and angiogenesis, and has been shown to be involved in the development and progression of breast cancer.

EMSY has also been shown to interact with the ERK1/2 signaling pathway, and inhibition of its activity has been shown to reduce the growth and survival of breast cancer cells. This suggests that EMSY may also be an effective drug target for breast cancer.

Conclusion

EMSY is a non-coding RNA molecule that has been identified as a potential drug target for breast cancer due to its ability to interact with BRCA2 and its role in the regulation of cellular processes that are important for cancer development. The inhibition of EMS

Protein Name: EMSY Transcriptional Repressor, BRCA2 Interacting

Functions: Regulator which is able to repress transcription, possibly via its interaction with a multiprotein chromatin remodeling complex that modifies the chromatin (PubMed:14651845). Its interaction with BRCA2 suggests that it may play a central role in the DNA repair function of BRCA2 (PubMed:14651845). Mediates ligand-dependent transcriptional activation by nuclear hormone receptors (PubMed:19131338)

The "EMSY Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EMSY comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets